News – Page 1180 – Endpoints News

AstraZeneca records another R&D setback, triggering a meltdown at Synairgen

9 years ago

The promise of designer microbes inspires a $130M mega-round for Zymergen

9 years ago

Auris tries to rebound from PhIII failure with new trial design; Kymab ties the knot with Shanghai-based EpimAb

9 years ago

Illumina shares tank after sequencing giant falls short on revenue

9 years ago

Novartis-backed Gamida Cell grabs a breakthrough trophy for experimental cell treatment

9 years ago

Supernus gets a (temporary) boost as ADHD drug clears PhIIb hurdle

9 years ago

Deaths, accusations of insider trading and an early warning from Boehringer stir Hanmi controversy

9 years ago

GSK attempts to remake itself in China with local ties

9 years ago

#ESMO16: Boehringer drug flops on OS endpoint; Medivir reorganizes, cuts staff

9 years ago

The Sarepta dilemma: Bioethics expert Arthur Caplan says it’s time to rethink how to regulate compassion

9 years ago

Takeda adds a $790M discovery deal to an ongoing R&D overhaul

9 years ago

Helsinn sets up a boutique investment fund with a roving eye for oncology upstarts

9 years ago

Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers

9 years ago

Novartis heads to the finish line with CDK 4/6 blockbuster contender ribociclib

9 years ago

Tesaro makes its case for a clean sweep with niraparib - and shares soar again

9 years ago

Kite touts 12-month remission data from tiny CAR-T study; Ironwood exec dies in bike accident

9 years ago

Thumbs Up/Thumbs Down: Major insurer delivers a bad blow to Duchenne families

9 years ago

Clovis shares tank after investors size up the disappointing data on rucaparib

9 years ago

Updated Incyte combo data for epacadostat/Keytruda look promising

9 years ago

Lethal experimental cancer drug from Hanmi, Boehringer killed three patients — report

9 years ago

Pfizer plots a big move (but it's not going very far)

9 years ago

Medicxi launches a diabetes upstart with $11M; Arrowhead partners on hep B; Immunotherapy startup gains $12.2M round

9 years ago

Reuters probe spotlights a conflict of interest between biotech investor F-Prime and giant Fidelity

9 years ago

Teva hands Celltrion $160M to grab US rights on two biosimilars of Roche blockbusters

9 years ago

First page Previous page 1177 1178 117911801181 1182 1183 Next page Last page